top of page
ALS Round Table (RT) Banners (1).png
ALS Round Table (RT) Banners (2).png

Access to this event is by invitation only.

We invite you to engage in an interactive nintely minute roundtable led by EverythingALS consortia of Pharma partners, sensor companies, neurologists, data scientists, regulators and patients to help advance the discovery and implementation of ALS digital biomarkers in clinical trials through our collaborative efforts.

 

Joining our participatory roundtable, you will be the first to learn about our latest study results on ALS digital biomarkers as well as have the opportunity to hear why major pharmaceutical companies have joined the consortium to partner in EverythingALS research, which will be expanded to include analyzing data from wearables and smartphones.

  

As always, we approach each roundtable to encourage out-of-the-box thinking, and to kick it off, we have an exciting agenda! Take a look below.         

Hosts & Speakers 

    Agenda

    Wednesday, December 10, 2025

    12:00 - 1:30 PM ET   I   9:00 AM - 10:30 PT

    10 minutes

    10 minutes

    5 minutes

    20 minutes

    20 minutes

    Welcome, with a preview of our 2025 Impact Report

    ​​Indu Navar, Founder & CEO, EverythingALS

    James Berry, Chief of the Division of ALS and MND, MGB, Harvard Medical

    Opening Keynote: Her Story, Person living with ALS

    .Ivonne Vaughn will share her journey of daily living with ALS

    New Consortium member introduction

    A discussion of why and what they bring to the consortia; what they would like to accomplish

    Transforming ALS Trial Recruitment: Removing Barriers to screening and enrollment with Generative AI - SAVA AI

    Co-present with Dr. Jinsy Andrews on how Sava, the GenAI can transform trial navigation, empower patients with clearer guidance, and deliver more accurate, personalized trial matching

    Advancing Clinical Endpoints: Speech-Listener's Effort, Gait/Balance

    Discus New Endpoint Developments, Analytics Enhancements, and Digital Biomarker Progress 

    Closed session

    END OPEN SESSION

     

    CONSORTIA MEMBERS' Only

    1:00-1:30 PM ET

    Agenda

    Participants

     

    © 2025 by EverythingALS

    EverythingALS is part of Peter Cohen Foundation, a non-profit 501(c)(3), United States. EIN 84-3055901 

    Email: info@everythingals.org

    bottom of page